Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oryzon Genomics SA
MAD:ORY
|
ES |
|
G
|
GN Store Nord A/S
F:GNN
|
DK |
|
Calnex Solutions PLC
F:CSO
|
UK |
|
Mainstreet Equity Corp
F:9V4
|
CA |
|
M
|
Mueller Industries Inc
F:MUD
|
US |
|
J
|
JVM Co Ltd
KOSDAQ:054950
|
KR |
|
Quest Diagnostics Inc
NYSE:DGX
|
US |
|
D
|
Dominion Energy Inc
DUS:DOD
|
US |
|
A
|
Artec Technologies AG
DUS:A6T
|
DE |
|
G
|
Gen Digital Inc
XHAN:SYM
|
US |
|
Thomson Reuters Corp
NASDAQ:TRI
|
CA |
|
J
|
Japan Metropolitan Fund Investment Corp
TSE:8953
|
JP |
|
Manolete Partners PLC
F:2BE
|
UK |
|
Suedwestdeutsche Salzwerke AG
F:SSH
|
DE |
|
A
|
APTIV PLC
XMUN:D7A
|
CH |
|
T
|
Thales SA
F:CSF
|
FR |
|
D
|
Danaher Corp
LSE:0R2B
|
US |
|
ALSOK Co Ltd
TSE:2331
|
JP |
|
A
|
Air China Ltd
SWB:AD2
|
CN |
|
Majestic Corporation PLC
OTC:MCJCF
|
UK |
|
Mitshi India Ltd
BSE:523782
|
IN |
|
KNR Constructions Ltd
BSE:532942
|
IN |
|
M
|
Mondelez International Inc
XHAM:KTF
|
US |
|
Hiab Oyj
F:C1C1
|
FI |
Bankruptcy Probability
Oryzon Genomics SA's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Oryzon Genomics SA Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ES |
|
Oryzon Genomics SA
MAD:ORY
|
217.2m EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
463.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
183.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
130B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
54.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
83.5B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
58.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
49.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
42B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Oryzon Genomics SA's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Oryzon Genomics SA has total debt of 1.7m EUR. This includes both short-term (0 EUR) and long-term (1.7m EUR) debt.
You can find a full breakdown on its Balance Sheet.